Expression of cell cycle proteins in T1 a and T1b urothelial bladder carcinoma and their value in predicting tumor progression

Cancer

Volumn 100, Issue 11, 2004, Pages 2367-2375

  Mhawech, Paulette ^a   Greloz, Vincent ^a   Oppikofer, Chantal ^a   Szalay Quinodoz, Idliko ^b   Herrmann, Francois ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cell cycle protein; Ki 67; Prediction of progression; T1a; T1b

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; PARAFFIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE PREPARATION; TUMOR GROWTH; UROGENITAL TRACT CANCER;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 2442700601     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20306     Document Type: Article

References (40)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Heney NM, Ahmed S, Flanadan MI, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:142-147.
3. Dixon JS, Gosling JA. Histology and fine structure of the muscularis mucosae of the human urinary baldder. J Anat. 1983;13:265-271.
4. Ro JY, Ayala AG, El-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol. 1987;11:668-673.
5. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990;66:543-548.
6. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in Stage T1 bladder cancer. Urology. 1995;45:47-53.
7. Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosa on the progression of superficial bladder cancer. Urology. 1994;43:782-786.
8. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in Stage T1 bladder carcinoma: a retrospective cohort study. J Urol. 1997;157:800-804.
9. Soloway MS, Sofer M, Vaidya A. Contemporary management of Stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-1583.
10. Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166:490-493.
11. Witjes JA, Kiemeney LALM, Schaafsma HE, Debruyne FMJ. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol. 1994;73:172-176.
12. Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of Stages TA and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol. 2000;164:1533-1537.
13. Knowles MA. What we could do now: molecular pathology of bladder cancer. J Clin Pathol Mol Pathol. 2001;54:215-221.
14. Shariat SF, Weizer AZ, Green A, et al. Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 200;56:735-740.
15. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in Stage T1 transitional cell bladder cancer. J Urol. 1998;159:91-94.
16. Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H. The predictive value of muscularis mucosae invasion and p53 over expression on progression of Stage T1 bladder carcinoma. J Urol. 2001;165:42-46.
17. Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. EJSO. 2003;29:74-80.
18. Mhawech P, Iselin C, Pelte MF. Value of immunohistochemistry in staging T1 urothelial baldder carcinoma. Eur Urol. 2002;42:459-463.
19. Epstein JI, Amin MB, Reuter VR, et al. Bladder Consensus Conference Committee: the World Health Organization consensus classification of urothelial neoplasms of the urinary bladder. Am J Surg Pathol. 1999;22:1435-1448.
20. Kononen J, Budendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:43:105-108.
21. Grossman HB, Liebert M, Antelo M, et al. p53 and Rb expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829-834.
22. Niehans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer. 1999;80:1175-1184.
23. Lee CC, Yamamoto S, Morimura K, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780-789.
24. Takagi Y, Takashi M, Koshikawa T, Sakata T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol. 2000;7:366-372.
25. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol. 1999;155:1129-1136.
26. Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World J Urol. 2002;20:190-195.
27. Helpap B, Scmitz-Drager BJ, Hamilton PW, et al. Molecular pathology of non-invasive urothelial carcinomas. Virchows Arch. 2003;442:309-316.
28. Korkolopoulou P, Christodoulou P, Lazaris A, et al. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. Eur Urol. 2001;39:167-177.
29. Friedrich MG, Blind C, Milde-Langosch K, et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol. 2001;40:518-524.
30. Orlow I, LaRue H, Osman I, et al. Deletions of the INK4A gene in superficial bladder tumors: association with recurrence. Am J Pathol. 1999;55:105-113.
31. Pfitser C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999;5:4079-4984.
32. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRB, and ki-67. Br J Cancer. 2001;84:270-275.
33. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75:1788-1792.
34. Sgambato A, Migaldi M, Faraglia B, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer. 2002;97:671-678.
35. Wagner U, Suess K, Luginbuhl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 1999;188:44-50.
36. Korkolopoulou P, Christodoulou P, Konstantinidou A-E, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27kip1. Hum Pathol. 2000;31:751-760.
37. Korkolopoulou P, Konstantinidou A-E, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P. WAF1/p21 expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunol Mol Morphol. 2000;8:285-292.
38. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072-1079.
39. Vorreuther R, Hake R, Borchmann P, Lukowsky S, Thiele J, Engelmann U. Expression of immunohistochemical markers (PCNA, Ki-67, 486p, and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors. Urol Int. 1997;59:88-94.
40. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in Stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997;157:800-804.